Andrew R. Colin, M.D., Joins AIT's Scientific Advisory Board

REHOVOT, Israel, August 7, 2013 /PRNewswire/ --

Israeli biomed company AIT (Advanced Inhalation Therapies Ltd.), a leader in the development of nitric oxide therapeutics for the treatment of infectious respiratory diseases, announced today the appointment of Andrew R. Colin, M.D., to its scientific advisory board.

Dr. Colin is a professor of pediatrics and director of the Division of Pediatric Pulmonology at the University of Miami Health System. He also serves as co-director of the Pediatric Cystic Fibrosis program. He is on the medical staff of Jackson Memorial Hospital in Miami, Florida. He is certified by the American Board of Pediatrics in pediatric pulmonology.

"I am delighted to welcome Dr. Andrew R. Colin to AIT's SAB. His tremendous expertise in the field of respiratory disease and pulmonology brings invaluable knowledge to AIT. This is a pivotal time for AIT as activities related to our Phase II clinical trials are expected in the coming months," says Professor Yossef Av-Gay, a director at AIT and a professor at the University of British Columbia in Vancouver, Canada.

"It is my privilege to be part of AIT, an innovative company with a leading team of researchers with proven results in clinical trials," said Dr. Colin. "I look forward to supporting AIT in the development of new therapeutics for patients with insufficient treatment options that lead to serious consequences."

AIT focuses on the development of unique nitric oxide formulations for the treatment of respiratory infectious diseases, including bronchiolitis, cystic fibrosis, pneumonia and asthma. The company is currently conducting Phase II trials for bronchiolitis in infants. Mid-study results demonstrated the safety of AIT's nitric oxide formulation in children.

About AIT

AIT (http://www.ait-pharm.com) is an Israeli biomed company focused on the development and commercialization of formulations from nitric oxide for the treatment of infectious diseases. The company was founded in 2011 by Mor Research Applications, a subsidiary of Clalit Health Services, Israel's largest health management organization.

The company is conducting Phase II trials on bronchiolitis after successful completion of Phase I trials. AIT develops products for the treatment of bronchiolitis, pneumonia, cystic fibrosis and asthma.

Contact information

Racheli Vizman, COO, AIT
2 Derech Meir Weisgal
Rehovot 9632605, Israel
E-mail: [email protected]
Direct: +972-8-684-3313
Mobile: +972-52-565-9922

SOURCE AIT - Advanced Inhalation Therapies Ltd.